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Abstract  
Periocular malignancies represent between 5% and 10% of all types of skin cancers. The incidence of eyelid (but 
also the periocular located) malignancies seems to differ in distribution across the continents.  The incidence of 
eyelid tumours (but also the periocular located tumours) in a predominantly white population determined that BCC 
is the most common malignant periocular eyelid tumour in whites. This finding has been replicated consistently 
throughout the literature, with BCC representing 85–95% of all eyelid malignancies, SCC representing 3.4 - 
12.6%, Seb Ca representing 0.6 - 10.2%, and both melanoma and Merkel cell carcinoma representing less than 
1%. Most periocular skin cancers are associated with ultraviolet radiation (UVR) exposure. Ultraviolet radiation 
causes local immune suppression, which, coupled with DNA abnormalities in tumour suppressor genes and 
oncogenes, leads to the development of skin cancers.  We are presenting a 62 - year - old patient with a small 
nodule about 2 cm away from the lower lid of his left eye. A tumour was surgically treated. Several years later 
there was a tumour relapse, treated with radiotherapy and subsequent chemotherapy with Endoxan and Cisplatin. 
After the second relapse, he was treated surgically in general anaesthesia by orbital exenteration, removal of the 
orbital floor and resection of zygomatic bone and the maxillary sinus. A couple of months later, he developed a 
tumour relapse in the scars and the area of a primary tumour with tumour progression. A possible therapy with 
Cetuximab or radiation therapy was discussed as a possible treatment option. 
 
 
 
 
 
 
 
 
Introduction 
 
Periocular SCC is a tumour with a possible 
unfavourable outcome, when not treated efficiently 
primarily. A recent study from Australia investigated 
the recurrence of SCC according to TNM 
classification. They observed a recurrence rate of 
5.3% (12/226 patients) for primary tumors and 20% 
(5/25 patients) for recurrent tumors (P = 0.019). 
Recurrences also occurred in T1 tumours.  Higher T 
stage was significantly associated with both perineural 
invasion and local recurrence [1].  
Perineural invasion capacity of periocular 
SCC bears a significant risk of orbital involvement and 
the need subsequent orbital exenteration [2]. There is 
a great variety of reconstructive procedures, but 
orbital prothesis and simple split skin grafts may be 
helpful as well [3].  
Adjuvant treatment with targeted tumour 
therapy is under investigation. Cetuximab has 
achieved a response rate of ≤ 47 %, erlotinib and 
gefitinib – to other epidermal growth factor tyrosine 
kinase inhibitors are under investigation in adjuvant 
and neoadjuvant settings [4][5][6].  
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Case presentation 
 
A 62 - year - old male patient presented in 
2009 with a small nodule about 2 cm away from the 
lower lid of his left eye. His medical history was 
positive for hypertension and unspecified hepatitis.  
The tumour was surgically removed elsewhere (Fig. 1 
a, b).  
 
Figure 1: a, b - Mutilating postoperative results and tumour relapse 
 
It was a squamous cell carcinoma (SCC), but 
the resection was obviously not R0. There was a 
relapse, and the tumour developed rapidly until 2013. 
From 09.09.13 to 13.09.13 radiotherapy had been 
performed. In March 2014, he received a single 
course of systemic chemotherapy with endoxan and 
cisplatin because of a second relapse. Computerized 
tomography (CT) revealed extended osteolysis of left 
sinus maxillaries, nasal bone and orbital bone. The 
polypoid soft tissue process involved not only sinus 
maxillaries and overlying subcutaneous adipose 
tissue but ocular bulbus as well. Chemotherapy was 
stopped.  
He was treated surgically in general 
anaesthesia by orbital exenteration, removal of the 
orbital floor and resection of zygomatic bone. The 
tumour resection included the maxillary sinus. The 
orbital defect was covered by temporal muscle. The 
soft tissue defect was closed by fronto-parietal 
rotational flap, buccal plasty, and a mesh graft 
obtained from his upper leg. A couple of months later, 
he developed a tumour relapse in the scars and the 
area of a primary tumour with tumour progress. 
 
 
 
 
Discussion 
 
The standard treatment for all eyelid 
carcinomas is surgical excision with negative margins, 
although controversy still exists regarding the 
recommended margins for each specific malignancy 
[7]. Mohs micrographic surgery has become the most 
common method of managing both BCC and SCC [8]. 
The benefits of this procedure lie in its capacity to 
determine margin control during excision and 
preserve the greatest amount of normal tissue [8]. 
This is especially significant in the eyelid and medial 
canthus, where large excisions can have devastating 
effects on the appearance and function of the eyelids 
[8]. Both frozen and permanent sectioning has been 
used for histologic assessment of surgical margins [8]. 
There does not seem to be a consensus in the 
literature regarding the preferred margin control 
technique for nonmelanoma malignancies [8]. 
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